Investigation of Potential Anticarcinogenic Effects of Corilagin in Lung Cancer Cells

Year 2019, Volume: 9 Issue: 3, 228 - 231, 30.09.2019

Cagla Rencuzogullari Zeynep Birsu Cincin Elif Sinem Iplik Yusuf Baran Bedia Cakmakoglu

https://doi.org/10.33808/clinexphealthsci.599707

Cited By: 2

Abstract

Objective: Lung cancer (LC) is the most extensive reason of cancer associated deaths in men and women in the world. LC categorizes into two main groups due to their molecular clinicopathological features and therapeutic responses. Non-small cell lung cancer (NSCLC) is the main subgroup that consists of nearly 85% of all lung cancer types. Corilagin, a biologically active ellagitannin, could be extracted from Phyllanthus species which are known as Chinese medicinal plant. It has been recently shown that Corilagin could exert anti-inflammatuar and antioxidative effects in different experimental cancer models. However, the molecular effects of Corilagin in NSCLC remain unclear.

Methods: In this study, the antiproliferative and apoptotic effects of Corilagin were identified by caspase-3 molecule and loss of mitochondrial membrane potential (MMP).

Results: We found that Corilagin significiantly suppressed the proliferation of NSCLC cells. Furthermore, we also showed that Corilagin could contribute apoprosis by inducing activity of caspase-3 molecule and loss of MMP.

Conclusion: Taken together, our study first showed that Corilagin could be a new treatment method for NSCLC after verifying its effects with in vivo and clinical studies.

Keywords

Corilagin, antiapoptotic, Non-small cell lung cancer

References

• 1. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12:175–180.
• 2. Travis WD. Classification of lung cancer. Semin Roentgenol 2011;46:178–186.
• 3. Wu Q, Chen YF, Fu J. et al. Short hairpin RNA-mediated down-regulation of CENPA attenuates the aggressive phenotype of lung adenocarcinoma cells. Cell Oncol 2014;37:399–407.
• 4. Koren A., Motaln H., Cufer T. Lung cancer stem cells: a biological and clinical perspective. Cell Oncol 2013;36: 265–275.
• 5. Peled N, Wynes MW, Ikeda N. et al. Hirsch, Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell Oncol 2013;36:277–288.
• 6. Maier A, Peille AL, Vuaroqueaux V. et al. Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts. Cell Oncol 2015. DOI 10.1007/s13402-014-0210-8.
• 7. Ulivi P, Silvestrini R. Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer. Cell Oncol 2013;36:439–448.
• 8. Giaccone G. Twenty-five years of treating advanced NSCLC: what have we achieved? Ann Oncol 2004;4:81–83.
• 9. Neal JW, Sequist LV. Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Curr Treat Options in Oncol 2010;11:36–44. 10. Sangha R, Lara PN, Mack PC. et al. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier. Curr Opin Oncol 2009;21:116–123. 11. Mateen S, Raina K, Agarwal R. Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer. Nutr Cancer J 2013;65:3–11.
• 12. Hau DKP, Gambari R, Wong RSM. et al. Phyllanthus urinaria extract attenuates acetamionophen induced hepatotoxicity: involvement of cytochrome P450 CYP2E1. Phytomedicine 2009;16:751– 760.
• 13. Shen ZQ, Dong ZJ, Peng H, Liu JK. Modulation of PAI-1 and tPA activity and thrombolytic effects of corilagin. Planta Med 2003;69:1109–12.
• 14. Sudjaroen YWE., Hull G, Erben et al. Isolation and characterization of ellagitannins as the major polyphenolic components of Longan (Dimocarpus longan Lour) seeds. Phytochemistry 2012;77:226–237.
• 15. Okabe S, Suganuma M, Imayoshi Y, et al. New TNF-𝛼 releasing inhibitors, geraniin and corilagin, in leaves of acer nikoense, megusurino-ki. Biological and Pharmaceutical Bulletin 2001;24,10:1145–1148.
• 16. Duan W, Yu Y, Zhang L. Antiatherogenic effects of phyllanthus emblica associated with corilagin and its analogue. Yakugaku Zasshi 2005;125:587–591.
• 17. Cheng JT, Lin TC, Hsu FL. Antihypertensive effect of corilagin in the rat. Can. J Physiol Pharmacol 1995;73:1425–1429.
• 18. Duan WG, Shen ZQ, Yan M. et al. Corilagin, a promising natural product to treat cardiovascular diseases. In: Phytopharmacology and Therapeutic Values II, J. N. Govil, V. K. Singh, and S. K. Mishra, Eds. 2008, pp. 163–172.
• 19. Kinoshita S, Inoue Y, Nakama S. et al. Antioxidant and hepatoprotective actions of medicinal herb, Terminalia catappa L. from Okinawa Island and its tannin corilagin. Phytomedicine 2007;14, 11: 755–762.
• 20. Hau DK, Zhu GY, Leung AK. et al. In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma. Phytomedicine 2010;15, 18(1):11-5.
• 21. Gambari R, Hau DK, Wong WY. et al. Sensitization of Hep3B hepatoma cells to cisplatin and doxorubicin by corilagin. Phytother Res 2014;28(5):781-3.
• 22. Ming Y, Zheng Z, Chen L. et al. Corilagin inhibits hepatocellular carcinoma cell proliferation by inducing G2/M phase arrest. Cell Biol Int 2013;37(10):1046-54.
• 23. Jia L, Jin H, Zhou J. et al. A potential anti-tumor herbal medicine, Corilagin, inhibits ovarian cancer cell growth through blocking the TGF-β signaling pathways. BMC Complement Altern Med 2013;15: 13:33.
• 24. Muresan XM, Cervellati F, Sticozzi C. et al. The loss of cellular junctions in epithelial lung cells induced by cigarette smoke is attenuated by corilagin. Oxid Med Cell Longev 2015;2015: 631758.
• 25. Wang Z, Guo QY, Zhang XJ. et al. Corilagin attenuates aerosol bleomycin-induced experimental lung injury. Int J Mol Sci 2014;30:15(6):9762-79.